David S. Hong

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +16

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations

Medicine, Oncology, Pharmacology +14

KRAS ^G12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Oncogenes +1

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 994 citations · Full text

Medicine, Oncology, Immunotherapy +14

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad et al. · British Journal of Cancer · 2020 · 912 citations · Full text

Medicine, Oncology, Pharmacology +13